{"altmetric_id":24476632,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Genentech, Inc."],"first_seen_on":"2017-08-29T11:12:26+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1503838006,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02353598"],"nct_id":"NCT02353598","pubdate":"2015-01-23T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":7,"3m":7,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8435952,"mean":7.094002543155,"rank":1238402,"this_scored_higher_than_pct":84,"this_scored_higher_than":7121625,"rank_type":"exact","sample_size":8435952,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":166143,"mean":12.485078463002,"rank":32808,"this_scored_higher_than_pct":79,"this_scored_higher_than":132376,"rank_type":"exact","sample_size":166143,"percentile":79},"this_journal":{"total_number_of_other_articles":24887,"mean":10.554122639235,"rank":4140,"this_scored_higher_than_pct":75,"this_scored_higher_than":18826,"rank_type":"exact","sample_size":24887,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":809,"mean":2.8158787128713,"rank":14,"this_scored_higher_than_pct":97,"this_scored_higher_than":789,"rank_type":"exact","sample_size":809,"percentile":97}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["alzforum"],"posts_count":1}},"posts":{"news":[{"title":"High-Dose A\u03b2 and Tau Immunotherapies Complete Initial Safety Tests","url":"http:\/\/ct.moreover.com\/?a=31647226879&p=1pl&v=1&x=4vbZt2pDzOvMF3kvnLiA3A","license":"public","citation_ids":[5073543,24476631,24476632,4942871,10850042],"posted_on":"2017-08-27T12:46:46+00:00","summary":"27 Aug 2017 Part 3 of a three-part story. Since A\u03b2 passive immunotherapy emerged as a potential treatment for Alzheimer\u2019s disease, drug developers have struggled with a major challenge\u2014how to get enough antibody into the brain to have the desired\u2026","author":{"name":"Alzforum","url":"http:\/\/www.alzforum.org","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/355\/normal\/Screen_Shot_2015-04-08_at_12.16.09_1.png?1428491784"}}]}}